Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Clinical evidence

OASISplus

36 evidence topics · 4 sources

Objective
Location and study date
Registered study dates and enrollment status
FieldReported value
Study start“2022-07-13”
Primary completion, estimated“2026-12”
Study completion, estimated“2027-03”
Recruitment status“Active, not recruiting”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse event incidence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
PopulationParticipants
Actual enrollment, both cohorts“154”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Open-label extension cohort: demographics and baseline attack rate
Switch cohort: demographics and baseline attack rate on prior prophylaxis
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Open-label extension cohort: treatment-emergent adverse events at year 1
Switch cohort: treatment-emergent adverse events at year 1
Study limitations
Summary

OASISplus is an open-label study with no comparator group, and both cohort publications summarized outcomes with descriptive statistics and no formal sample size calculation.

The open-label extension cohort enrolled 83 of the 90 OASIS-HAE participants (69 receiving donidalorsen every 4 weeks and 14 every 8 weeks). Participants continued every-8-week dosing only if they had been attack-free during the last 8 weeks of OASIS-HAE, so the every-8-week group of 14 participants was selected for response. The 94% and 95% reductions are measured from the OASIS-HAE baseline, before any prophylaxis in that trial.

The Switch cohort dosed 64 participants who had been receiving lanadelumab (31), berotralstat (11), or C1 inhibitor (22). Its attack-rate baseline was the screening period on the prior prophylactic treatment (mean 0.85 attacks per month), so the 67.6% reduction is a within-participant comparison with continued prior prophylaxis, without randomization or blinding. Eleven participants (16.9%) discontinued during the first year, including 4 who had switched from lanadelumab and discontinued for lack of efficacy. The subgroups by prior therapy contain 11 to 31 participants, which limits precision for comparisons between them.

In both cohorts, 89.1% to 91.6% of participants were White. The registry lists an actual enrollment of 154 participants across the study, and the two cohort publications report 83 and 65 participants enrolled. The year 1 publications report data through January 27, 2025, and the registry lists treatment for up to 157 weeks, with primary completion estimated for December 2026.